Posted on December 4th 2024
For the last few months, we’ve been working in collaboration with the specialist centres, homecare delivery companies, and drug manufacturers GSK to bring you regular updates on supply issues related to Flolan – which is also called epoprostenol.
Following an update on 3rd December 2024, we can now confirm that there are full, safe stock levels at suppliers’ warehouses and homecare companies. This means that all supply restrictions have been lifted so affected centres will be able to prescribe Flolan to patients starting on intravenous epoprostenol again. The normal schedule of providing four-week deliveries to patients will continue.
The PHA UK, along with PH teams from every affected centre, have met regularly with homecare delivery companies and GSK since the ‘pause in supply’ in March to lessen any potential impact for patients.
We continue to hold GSK to account for the supply delays and for the anxiety that these issues have caused within our PH community this year. A meeting will take place with them in early 2025 to build closer working relationships, improve communication, and take steps to ensure this does not happen again.
